Daclahep (Daclatasvir Dihydrochloride)

150.009,999.00

Daclahep (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.

Description

Daclahep (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.

Dosage and AdministrationThe recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. It can be taken with or without food.

Treatment with Daclahep (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.

Daclahep should always be taken concurrently with Sofosbuvir.

Daclahep should be taken with Sofosbuvir and Ribavarin in the following cases:

  • Genotype 1 infection with decompensated cirrhosis
  • Genotype 1 infection post-transplant
  • Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis
  • Genotype 3 infection post-transplant
Side effectsThe most common side effects associated with Daclahep (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.

When Daclahep is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.

PrecautionsAmiodarone when used with Daclahep and Sofosbuvir has caused in serious symptomatic bradycardia in some patients. The risk of bradycardia is increased in patients who are taking beta-blockers or patients with heart problems or liver disease.

Daclatasvir is contraindicated when taking strong inducers of CYP3A, including phenytoin, carbamazepine, rifampin, and St. John’s wort.

The following medicines are known to interact with Daclatasvir:

  • Protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
  • Other antiretrovirals (eg. atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)
  • Non-nucleoside reverse transcriptase inhibitors (efavirenzb, etravirine, nevirapine)
  • Strong CYP3A inhibitors (eg. clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, voriconazole)
  • Moderate CYP3A inducers (eg. bosentan, dexamethasone, modafinil, nafcillin, rifapentine)
  • Anticoagulants (dabigatran etexilate mesylate)
  • Cardiovascular agents (Amiodarone, Digoxin)
  • HMG-CoA reductase inhibitors (Atorvastatin, Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin)
  • Narcotic Analgesics (buprenorphine, buprenorphine/naloxone)

Daclatasvir may increase the risk of birth defects and miscarriage. Before taking daclatasvir, tell your doctor if:

  • you are pregnant, trying to become pregnant or breast-feeding
  • your partner is pregnant or trying to become pregnant

Safety of Daclatasvir in patients under 18 years has not been established.

Additional information

Quantity

1 Bottle (s), 3 Bottles(s), 5 Bottle(s), 10 Bottle {s}, 100 Bottle {s}